drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous gene-modified T cells engineered to express a dual-target chimeric antigen receptor recognizing TIM-3 and CD123, designed to induce T-cell mediated cytotoxicity against TIM-3+ CD123+ leukemia stem cells and CD123+ AML blasts while sparing normal hematopoietic cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a dual-target chimeric antigen receptor that recognizes TIM-3 and CD123. Antigen engagement on TIM-3+ CD123+ leukemia stem cells and CD123+ AML blasts activates CAR signaling (CD3zeta/co-stimulation), driving T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing. Dual recognition is intended to enhance specificity and reduce on-target/off-tumor toxicity to normal hematopoietic cells, which have minimal TIM-3 expression.
drug_name
Anti-TIM-3/CD123 CAR-T cells
nct_id_drug_ref
NCT06125652